IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC
The original patent application was initiated by the University of South Florida (“USF”) and filed on July 30, 2015. On May 25, 2017, IGC entered into an exclusive license agreement with USF with respect to the patent application and the associated research conducted on Alzheimer’s disease.
IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia from Alzheimer’s Disease.
Company To Host Conference Call on Friday, December 2 at 11 a.m. ET
